Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 368

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 368
---
 diarrhea of unknown origin, recurrent Clostridium difficile infection, untreated Helicobacter pylori infection, and chronic constipation also constituted grounds for exclusion. Furthermore, individuals who had consumed any antibiotics (oral or intravenous), corticoids (oral, intravenous, intramuscular, nasal, or inhaled), cytokines, drugs stimulating the immune system (such as interleukins), cytotoxic agents (chemotherapy), or large doses of probiotics within the last six months prior to sampling were excluded. Additional exclusion factors included a diagnosis of any disease in the previous six months, chronic use of any type of medication, habitual vegan or vegetarian diets, and a Body Mass Index (BMI) exceeding 29.99, indicating obesity. Following the above criteria, 172 volunteers were accepted for biochemical and metabolome analysis from blood and urine samples, and microbiome analysis from stool samples. These resulted in a total of 516 biological samples processed in the laboratory for biochemical, metabolome, and microbiome data. To enhance analysis accuracy, epidemiological and contextual metadata was collected from each volunteer using a questionnaire for general background information diet, clinical history, gestational history, and medication history was collected. Rewell leverages this comprehensive reference data to provide scientifically precise results, enabling users to manage their long -termhealth. This precision extends to detecting dysbiosis or imbalances in specific microbiome parameters by comparing customer samples against our reference dataset. We ran pilot tests to verify if this method could effectively detect differences in people’s gut microbiomes and provide a positive impact, and the results showed it works consistently well. The pilot test, which was sponsored by Heritas Argentina and CIBIC, was carried out in an Argentinian population between October 2022 and March 2024. A total of 634 individuals participated, and their gut microbiomes were respectively analyzed. The results revealed key patterns. For example: 52.84% of the participants had lower gut microbiome diversity than the average levels in our reference database, which can impact overall health (p<0.001). Additionally, 65.88% of participants produced fewer short -chainfatty acids, essential compounds that support metabolism and overall well -being, compared to typical levels in our reference database (p<0.001). We also found that participants had lower levels of gut bacteria diversity and balance, as well as a reduced ability to produce not only short -chainfatty acids but also essential nutrients like vitamins B1 (p=0.008),